nodes	percent_of_prediction	percent_of_DWPC	metapath
Aripiprazole—CYP2D6—breast cancer	0.0826	0.389	CbGaD
Aripiprazole—CYP3A4—breast cancer	0.0708	0.334	CbGaD
Aripiprazole—ABCB1—breast cancer	0.059	0.278	CbGaD
Aripiprazole—HTR6—Raloxifene—breast cancer	0.0448	0.115	CbGbCtD
Aripiprazole—HTR2B—Raloxifene—breast cancer	0.04	0.102	CbGbCtD
Aripiprazole—CYP3A5—Lapatinib—breast cancer	0.0168	0.043	CbGbCtD
Aripiprazole—ABCB1—Toremifene—breast cancer	0.015	0.0384	CbGbCtD
Aripiprazole—CYP3A4—Exemestane—breast cancer	0.013	0.0332	CbGbCtD
Aripiprazole—CYP2D6—Idarubicin—breast cancer	0.0117	0.03	CbGbCtD
Aripiprazole—CYP3A7—Tamoxifen—breast cancer	0.0112	0.0287	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Tamoxifen—breast cancer	0.0112	0.0287	CbGbCtD
Aripiprazole—CYP3A4—Letrozole—breast cancer	0.011	0.0282	CbGbCtD
Aripiprazole—ABCB1—Lapatinib—breast cancer	0.0109	0.028	CbGbCtD
Aripiprazole—CYP3A4—Anastrozole—breast cancer	0.00982	0.0251	CbGbCtD
Aripiprazole—CYP3A4—Toremifene—breast cancer	0.00898	0.023	CbGbCtD
Aripiprazole—CYP3A7—Paclitaxel—breast cancer	0.00873	0.0223	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Paclitaxel—breast cancer	0.00873	0.0223	CbGbCtD
Aripiprazole—CYP3A7—Irinotecan—breast cancer	0.00862	0.022	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Irinotecan—breast cancer	0.00862	0.022	CbGbCtD
Aripiprazole—CYP3A5—Tamoxifen—breast cancer	0.00842	0.0215	CbGbCtD
Aripiprazole—CYP3A4—Fulvestrant—breast cancer	0.00835	0.0214	CbGbCtD
Aripiprazole—CYP3A4—Thiotepa—breast cancer	0.00744	0.019	CbGbCtD
Aripiprazole—CYP3A4—Ixabepilone—breast cancer	0.00681	0.0174	CbGbCtD
Aripiprazole—CYP3A4—Lapatinib—breast cancer	0.00655	0.0168	CbGbCtD
Aripiprazole—CYP3A5—Paclitaxel—breast cancer	0.00655	0.0168	CbGbCtD
Aripiprazole—CYP3A5—Irinotecan—breast cancer	0.00646	0.0165	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Docetaxel—breast cancer	0.00631	0.0162	CbGbCtD
Aripiprazole—CYP3A7—Docetaxel—breast cancer	0.00631	0.0162	CbGbCtD
Aripiprazole—ABCB1—Vinorelbine—breast cancer	0.00607	0.0155	CbGbCtD
Aripiprazole—CYP2D6—Vinorelbine—breast cancer	0.00572	0.0146	CbGbCtD
Aripiprazole—ABCB1—Tamoxifen—breast cancer	0.00548	0.014	CbGbCtD
Aripiprazole—ABCB1—Mitoxantrone—breast cancer	0.00534	0.0137	CbGbCtD
Aripiprazole—CYP2D6—Tamoxifen—breast cancer	0.00516	0.0132	CbGbCtD
Aripiprazole—CYP3A4—Raloxifene—breast cancer	0.00497	0.0127	CbGbCtD
Aripiprazole—CYP3A5—Docetaxel—breast cancer	0.00474	0.0121	CbGbCtD
Aripiprazole—ABCB1—Gemcitabine—breast cancer	0.00472	0.0121	CbGbCtD
Aripiprazole—ABCB1—Paclitaxel—breast cancer	0.00426	0.0109	CbGbCtD
Aripiprazole—ABCB1—Irinotecan—breast cancer	0.00421	0.0108	CbGbCtD
Aripiprazole—ABCB1—Vinblastine—breast cancer	0.00374	0.00957	CbGbCtD
Aripiprazole—CYP3A4—Vinorelbine—breast cancer	0.00364	0.0093	CbGbCtD
Aripiprazole—CYP2D6—Vinblastine—breast cancer	0.00352	0.00902	CbGbCtD
Aripiprazole—CYP3A4—Tamoxifen—breast cancer	0.00328	0.0084	CbGbCtD
Aripiprazole—CYP3A4—Mitoxantrone—breast cancer	0.0032	0.00819	CbGbCtD
Aripiprazole—ABCB1—Docetaxel—breast cancer	0.00308	0.00789	CbGbCtD
Aripiprazole—CHRM3—muscle of abdomen—breast cancer	0.003	0.0843	CbGeAlD
Aripiprazole—CYP3A4—Paclitaxel—breast cancer	0.00255	0.00654	CbGbCtD
Aripiprazole—CYP3A4—Irinotecan—breast cancer	0.00252	0.00645	CbGbCtD
Aripiprazole—ABCB1—Doxorubicin—breast cancer	0.0023	0.00588	CbGbCtD
Aripiprazole—CYP3A4—Vinblastine—breast cancer	0.00224	0.00573	CbGbCtD
Aripiprazole—ABCB1—Methotrexate—breast cancer	0.00223	0.0057	CbGbCtD
Aripiprazole—CYP2D6—Doxorubicin—breast cancer	0.00216	0.00554	CbGbCtD
Aripiprazole—CYP3A4—Docetaxel—breast cancer	0.00185	0.00473	CbGbCtD
Aripiprazole—CYP3A4—Doxorubicin—breast cancer	0.00138	0.00352	CbGbCtD
Aripiprazole—H1F0—mammary gland—breast cancer	0.000989	0.0278	CbGeAlD
Aripiprazole—H1F0—nipple—breast cancer	0.000818	0.023	CbGeAlD
Aripiprazole—H1F0—embryo—breast cancer	0.000675	0.019	CbGeAlD
Aripiprazole—CHRM5—epithelium—breast cancer	0.000638	0.0179	CbGeAlD
Aripiprazole—HTR1E—female gonad—breast cancer	0.00063	0.0177	CbGeAlD
Aripiprazole—CHRM5—skin of body—breast cancer	0.000607	0.0171	CbGeAlD
Aripiprazole—DRD5—female reproductive system—breast cancer	0.000529	0.0149	CbGeAlD
Aripiprazole—H1F0—skin of body—breast cancer	0.000524	0.0147	CbGeAlD
Aripiprazole—H1F0—endometrium—breast cancer	0.000494	0.0139	CbGeAlD
Aripiprazole—Cilostazol—CYP2D6—breast cancer	0.000482	0.164	CrCbGaD
Aripiprazole—DRD5—female gonad—breast cancer	0.000481	0.0135	CbGeAlD
Aripiprazole—KCNH2—nipple—breast cancer	0.00047	0.0132	CbGeAlD
Aripiprazole—CYP3A7—endocrine gland—breast cancer	0.000467	0.0131	CbGeAlD
Aripiprazole—ADRA2C—nipple—breast cancer	0.000464	0.013	CbGeAlD
Aripiprazole—H1F0—uterus—breast cancer	0.000455	0.0128	CbGeAlD
Aripiprazole—DRD5—endocrine gland—breast cancer	0.000447	0.0126	CbGeAlD
Aripiprazole—H1F0—pituitary gland—breast cancer	0.000447	0.0126	CbGeAlD
Aripiprazole—H1F0—adipose tissue—breast cancer	0.000445	0.0125	CbGeAlD
Aripiprazole—Cilostazol—CYP3A4—breast cancer	0.000413	0.141	CrCbGaD
Aripiprazole—Vilazodone—CYP2D6—breast cancer	0.00041	0.14	CrCbGaD
Aripiprazole—H1F0—female reproductive system—breast cancer	0.000409	0.0115	CbGeAlD
Aripiprazole—H1F0—adrenal gland—breast cancer	0.000399	0.0112	CbGeAlD
Aripiprazole—H1F0—bone marrow—breast cancer	0.000386	0.0109	CbGeAlD
Aripiprazole—HTR2B—skin of body—breast cancer	0.000377	0.0106	CbGeAlD
Aripiprazole—HRH1—nipple—breast cancer	0.000377	0.0106	CbGeAlD
Aripiprazole—H1F0—female gonad—breast cancer	0.000372	0.0105	CbGeAlD
Aripiprazole—ADRA2A—nipple—breast cancer	0.00037	0.0104	CbGeAlD
Aripiprazole—HTR2B—endometrium—breast cancer	0.000356	0.01	CbGeAlD
Aripiprazole—Vilazodone—CYP3A4—breast cancer	0.000351	0.12	CrCbGaD
Aripiprazole—H1F0—endocrine gland—breast cancer	0.000346	0.00973	CbGeAlD
Aripiprazole—HTR7—epithelium—breast cancer	0.00034	0.00955	CbGeAlD
Aripiprazole—ADRB1—adipose tissue—breast cancer	0.000335	0.00941	CbGeAlD
Aripiprazole—HTR2B—uterus—breast cancer	0.000328	0.00921	CbGeAlD
Aripiprazole—ADRA1A—epithelium—breast cancer	0.000328	0.00921	CbGeAlD
Aripiprazole—HTR1B—female reproductive system—breast cancer	0.000327	0.0092	CbGeAlD
Aripiprazole—HTR2B—adipose tissue—breast cancer	0.000321	0.00901	CbGeAlD
Aripiprazole—HTR1D—female reproductive system—breast cancer	0.000317	0.00891	CbGeAlD
Aripiprazole—HTR2C—female reproductive system—breast cancer	0.000314	0.00882	CbGeAlD
Aripiprazole—ADRB1—female reproductive system—breast cancer	0.000308	0.00865	CbGeAlD
Aripiprazole—SLC6A4—female reproductive system—breast cancer	0.000297	0.00836	CbGeAlD
Aripiprazole—CHRM1—female reproductive system—breast cancer	0.000296	0.00833	CbGeAlD
Aripiprazole—HTR2B—female reproductive system—breast cancer	0.000295	0.00828	CbGeAlD
Aripiprazole—CHRM3—adipose tissue—breast cancer	0.000289	0.00811	CbGeAlD
Aripiprazole—HTR2B—adrenal gland—breast cancer	0.000288	0.00808	CbGeAlD
Aripiprazole—KCNH2—endometrium—breast cancer	0.000284	0.00798	CbGeAlD
Aripiprazole—ADRA2C—endometrium—breast cancer	0.00028	0.00787	CbGeAlD
Aripiprazole—HTR1B—endocrine gland—breast cancer	0.000277	0.00778	CbGeAlD
Aripiprazole—CHRM2—endocrine gland—breast cancer	0.000275	0.00774	CbGeAlD
Aripiprazole—CHRM3—female reproductive system—breast cancer	0.000265	0.00745	CbGeAlD
Aripiprazole—ADRA1A—adipose tissue—breast cancer	0.000265	0.00744	CbGeAlD
Aripiprazole—KCNH2—uterus—breast cancer	0.000262	0.00735	CbGeAlD
Aripiprazole—DRD2—pituitary gland—breast cancer	0.000261	0.00733	CbGeAlD
Aripiprazole—ADRB1—endocrine gland—breast cancer	0.000261	0.00732	CbGeAlD
Aripiprazole—HTR2A—embryo—breast cancer	0.00026	0.0073	CbGeAlD
Aripiprazole—ADRA2C—uterus—breast cancer	0.000258	0.00725	CbGeAlD
Aripiprazole—HTR1A—adrenal gland—breast cancer	0.000258	0.00724	CbGeAlD
Aripiprazole—KCNH2—pituitary gland—breast cancer	0.000257	0.00722	CbGeAlD
Aripiprazole—HRH1—epithelium—breast cancer	0.000254	0.00713	CbGeAlD
Aripiprazole—ADRA2C—pituitary gland—breast cancer	0.000253	0.00712	CbGeAlD
Aripiprazole—HTR7—female reproductive system—breast cancer	0.000252	0.00709	CbGeAlD
Aripiprazole—ADRA2C—adipose tissue—breast cancer	0.000252	0.00709	CbGeAlD
Aripiprazole—SLC6A4—endocrine gland—breast cancer	0.000252	0.00707	CbGeAlD
Aripiprazole—CHRM1—endocrine gland—breast cancer	0.000251	0.00705	CbGeAlD
Aripiprazole—HTR7—adrenal gland—breast cancer	0.000246	0.00692	CbGeAlD
Aripiprazole—CHRM3—female gonad—breast cancer	0.000241	0.00678	CbGeAlD
Aripiprazole—H1F0—lymph node—breast cancer	0.000239	0.00672	CbGeAlD
Aripiprazole—ADRA1A—adrenal gland—breast cancer	0.000238	0.00668	CbGeAlD
Aripiprazole—KCNH2—female reproductive system—breast cancer	0.000235	0.00661	CbGeAlD
Aripiprazole—KCNH2—adrenal gland—breast cancer	0.000229	0.00645	CbGeAlD
Aripiprazole—HRH1—endometrium—breast cancer	0.000228	0.00639	CbGeAlD
Aripiprazole—ADRA2C—adrenal gland—breast cancer	0.000226	0.00636	CbGeAlD
Aripiprazole—CHRM3—endocrine gland—breast cancer	0.000224	0.00631	CbGeAlD
Aripiprazole—HTR1A—endocrine gland—breast cancer	0.000224	0.00628	CbGeAlD
Aripiprazole—ADRA2A—endometrium—breast cancer	0.000223	0.00628	CbGeAlD
Aripiprazole—KCNH2—bone marrow—breast cancer	0.000222	0.00624	CbGeAlD
Aripiprazole—KCNH2—female gonad—breast cancer	0.000214	0.00601	CbGeAlD
Aripiprazole—HTR7—endocrine gland—breast cancer	0.000214	0.006	CbGeAlD
Aripiprazole—HTR2A—epithelium—breast cancer	0.000212	0.00595	CbGeAlD
Aripiprazole—CYP3A5—adipose tissue—breast cancer	0.000211	0.00594	CbGeAlD
Aripiprazole—ADRA2C—female gonad—breast cancer	0.000211	0.00593	CbGeAlD
Aripiprazole—ADRA1A—endocrine gland—breast cancer	0.000206	0.00579	CbGeAlD
Aripiprazole—ADRA2A—uterus—breast cancer	0.000206	0.00579	CbGeAlD
Aripiprazole—HRH1—adipose tissue—breast cancer	0.000205	0.00576	CbGeAlD
Aripiprazole—ADRA2A—pituitary gland—breast cancer	0.000202	0.00568	CbGeAlD
Aripiprazole—DRD2—endocrine gland—breast cancer	0.000202	0.00568	CbGeAlD
Aripiprazole—ADRA2A—adipose tissue—breast cancer	0.000201	0.00566	CbGeAlD
Aripiprazole—KCNH2—endocrine gland—breast cancer	0.000199	0.00559	CbGeAlD
Aripiprazole—HRH1—female reproductive system—breast cancer	0.000188	0.0053	CbGeAlD
Aripiprazole—ADRA2A—female reproductive system—breast cancer	0.000185	0.0052	CbGeAlD
Aripiprazole—HRH1—adrenal gland—breast cancer	0.000184	0.00517	CbGeAlD
Aripiprazole—ADRA2A—adrenal gland—breast cancer	0.000181	0.00508	CbGeAlD
Aripiprazole—CYP3A5—female gonad—breast cancer	0.000177	0.00497	CbGeAlD
Aripiprazole—HTR2B—lymph node—breast cancer	0.000172	0.00485	CbGeAlD
Aripiprazole—HTR2A—pituitary gland—breast cancer	0.000172	0.00483	CbGeAlD
Aripiprazole—HRH1—female gonad—breast cancer	0.000171	0.00482	CbGeAlD
Aripiprazole—ABCB1—embryo—breast cancer	0.00017	0.00478	CbGeAlD
Aripiprazole—ADRA2A—female gonad—breast cancer	0.000168	0.00473	CbGeAlD
Aripiprazole—CYP3A5—endocrine gland—breast cancer	0.000164	0.00462	CbGeAlD
Aripiprazole—HRH1—endocrine gland—breast cancer	0.000159	0.00448	CbGeAlD
Aripiprazole—HTR2A—female reproductive system—breast cancer	0.000157	0.00442	CbGeAlD
Aripiprazole—ADRA2A—endocrine gland—breast cancer	0.000157	0.0044	CbGeAlD
Aripiprazole—Ziprasidone—CYP2D6—breast cancer	0.000155	0.0529	CrCbGaD
Aripiprazole—HTR2A—adrenal gland—breast cancer	0.000154	0.00432	CbGeAlD
Aripiprazole—CYP3A4—female reproductive system—breast cancer	0.000146	0.0041	CbGeAlD
Aripiprazole—CYP2D6—female reproductive system—breast cancer	0.000143	0.00403	CbGeAlD
Aripiprazole—ABCB1—epithelium—breast cancer	0.000139	0.0039	CbGeAlD
Aripiprazole—KCNH2—lymph node—breast cancer	0.000138	0.00387	CbGeAlD
Aripiprazole—ADRA2C—lymph node—breast cancer	0.000136	0.00381	CbGeAlD
Aripiprazole—HTR2A—endocrine gland—breast cancer	0.000133	0.00374	CbGeAlD
Aripiprazole—Ziprasidone—CYP3A4—breast cancer	0.000133	0.0454	CrCbGaD
Aripiprazole—CYP2D6—female gonad—breast cancer	0.00013	0.00367	CbGeAlD
Aripiprazole—Nefazodone—CYP2D6—breast cancer	0.00013	0.0444	CrCbGaD
Aripiprazole—ABCB1—endometrium—breast cancer	0.000125	0.0035	CbGeAlD
Aripiprazole—CYP3A4—endocrine gland—breast cancer	0.000123	0.00347	CbGeAlD
Aripiprazole—CYP2D6—endocrine gland—breast cancer	0.000121	0.00341	CbGeAlD
Aripiprazole—Trazodone—CYP2D6—breast cancer	0.000121	0.0411	CrCbGaD
Aripiprazole—ABCB1—uterus—breast cancer	0.000115	0.00322	CbGeAlD
Aripiprazole—ABCB1—pituitary gland—breast cancer	0.000113	0.00317	CbGeAlD
Aripiprazole—ABCB1—adipose tissue—breast cancer	0.000112	0.00315	CbGeAlD
Aripiprazole—Nefazodone—CYP3A4—breast cancer	0.000112	0.0381	CrCbGaD
Aripiprazole—HRH1—lymph node—breast cancer	0.00011	0.0031	CbGeAlD
Aripiprazole—ADRA2A—lymph node—breast cancer	0.000108	0.00304	CbGeAlD
Aripiprazole—Prochlorperazine—CYP2D6—breast cancer	0.000108	0.0368	CrCbGaD
Aripiprazole—Trazodone—CYP3A4—breast cancer	0.000103	0.0353	CrCbGaD
Aripiprazole—ABCB1—female reproductive system—breast cancer	0.000103	0.0029	CbGeAlD
Aripiprazole—ABCB1—adrenal gland—breast cancer	0.000101	0.00283	CbGeAlD
Aripiprazole—ABCB1—bone marrow—breast cancer	9.74e-05	0.00274	CbGeAlD
Aripiprazole—ABCB1—female gonad—breast cancer	9.39e-05	0.00264	CbGeAlD
Aripiprazole—Nefazodone—ABCB1—breast cancer	9.31e-05	0.0317	CrCbGaD
Aripiprazole—Prochlorperazine—CYP3A4—breast cancer	9.26e-05	0.0316	CrCbGaD
Aripiprazole—ABCB1—endocrine gland—breast cancer	8.73e-05	0.00245	CbGeAlD
Aripiprazole—Trazodone—ABCB1—breast cancer	8.61e-05	0.0294	CrCbGaD
Aripiprazole—Perphenazine—CYP2D6—breast cancer	7.72e-05	0.0263	CrCbGaD
Aripiprazole—Perphenazine—CYP3A4—breast cancer	6.62e-05	0.0226	CrCbGaD
Aripiprazole—ABCB1—lymph node—breast cancer	6.03e-05	0.0017	CbGeAlD
Aripiprazole—Dyspnoea—Capecitabine—breast cancer	1.5e-05	6.28e-05	CcSEcCtD
Aripiprazole—Fatigue—Docetaxel—breast cancer	1.5e-05	6.27e-05	CcSEcCtD
Aripiprazole—Angiopathy—Epirubicin—breast cancer	1.5e-05	6.26e-05	CcSEcCtD
Aripiprazole—Urethral disorder—Doxorubicin—breast cancer	1.5e-05	6.26e-05	CcSEcCtD
Aripiprazole—Nausea—Mitoxantrone—breast cancer	1.49e-05	6.25e-05	CcSEcCtD
Aripiprazole—Nausea—Irinotecan—breast cancer	1.49e-05	6.25e-05	CcSEcCtD
Aripiprazole—Immune system disorder—Epirubicin—breast cancer	1.49e-05	6.23e-05	CcSEcCtD
Aripiprazole—Mediastinal disorder—Epirubicin—breast cancer	1.49e-05	6.22e-05	CcSEcCtD
Aripiprazole—Constipation—Docetaxel—breast cancer	1.49e-05	6.22e-05	CcSEcCtD
Aripiprazole—Pain—Docetaxel—breast cancer	1.49e-05	6.22e-05	CcSEcCtD
Aripiprazole—Back pain—Methotrexate—breast cancer	1.48e-05	6.21e-05	CcSEcCtD
Aripiprazole—Dyspepsia—Capecitabine—breast cancer	1.48e-05	6.2e-05	CcSEcCtD
Aripiprazole—Chills—Epirubicin—breast cancer	1.48e-05	6.19e-05	CcSEcCtD
Aripiprazole—Visual impairment—Doxorubicin—breast cancer	1.47e-05	6.16e-05	CcSEcCtD
Aripiprazole—Asthenia—Paclitaxel—breast cancer	1.47e-05	6.15e-05	CcSEcCtD
Aripiprazole—Decreased appetite—Capecitabine—breast cancer	1.46e-05	6.12e-05	CcSEcCtD
Aripiprazole—Alopecia—Epirubicin—breast cancer	1.46e-05	6.1e-05	CcSEcCtD
Aripiprazole—Nausea—Gemcitabine—breast cancer	1.45e-05	6.09e-05	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Capecitabine—breast cancer	1.45e-05	6.08e-05	CcSEcCtD
Aripiprazole—Fatigue—Capecitabine—breast cancer	1.45e-05	6.07e-05	CcSEcCtD
Aripiprazole—Pruritus—Paclitaxel—breast cancer	1.45e-05	6.07e-05	CcSEcCtD
Aripiprazole—Vision blurred—Methotrexate—breast cancer	1.45e-05	6.05e-05	CcSEcCtD
Aripiprazole—Mental disorder—Epirubicin—breast cancer	1.45e-05	6.05e-05	CcSEcCtD
Aripiprazole—Pain—Capecitabine—breast cancer	1.44e-05	6.02e-05	CcSEcCtD
Aripiprazole—Constipation—Capecitabine—breast cancer	1.44e-05	6.02e-05	CcSEcCtD
Aripiprazole—Erythema—Epirubicin—breast cancer	1.44e-05	6.01e-05	CcSEcCtD
Aripiprazole—Malnutrition—Epirubicin—breast cancer	1.44e-05	6.01e-05	CcSEcCtD
Aripiprazole—Feeling abnormal—Docetaxel—breast cancer	1.43e-05	5.99e-05	CcSEcCtD
Aripiprazole—Nausea—Fluorouracil—breast cancer	1.43e-05	5.98e-05	CcSEcCtD
Aripiprazole—Eye disorder—Doxorubicin—breast cancer	1.43e-05	5.97e-05	CcSEcCtD
Aripiprazole—Ill-defined disorder—Methotrexate—breast cancer	1.42e-05	5.96e-05	CcSEcCtD
Aripiprazole—Tinnitus—Doxorubicin—breast cancer	1.42e-05	5.96e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Docetaxel—breast cancer	1.42e-05	5.95e-05	CcSEcCtD
Aripiprazole—Anaemia—Methotrexate—breast cancer	1.42e-05	5.93e-05	CcSEcCtD
Aripiprazole—Flushing—Doxorubicin—breast cancer	1.42e-05	5.93e-05	CcSEcCtD
Aripiprazole—Cardiac disorder—Doxorubicin—breast cancer	1.42e-05	5.93e-05	CcSEcCtD
Aripiprazole—Flatulence—Epirubicin—breast cancer	1.42e-05	5.92e-05	CcSEcCtD
Aripiprazole—Tension—Epirubicin—breast cancer	1.41e-05	5.9e-05	CcSEcCtD
Aripiprazole—Dysgeusia—Epirubicin—breast cancer	1.41e-05	5.88e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Paclitaxel—breast cancer	1.4e-05	5.87e-05	CcSEcCtD
Aripiprazole—Nervousness—Epirubicin—breast cancer	1.4e-05	5.84e-05	CcSEcCtD
Aripiprazole—Back pain—Epirubicin—breast cancer	1.39e-05	5.81e-05	CcSEcCtD
Aripiprazole—Feeling abnormal—Capecitabine—breast cancer	1.39e-05	5.8e-05	CcSEcCtD
Aripiprazole—Angiopathy—Doxorubicin—breast cancer	1.39e-05	5.79e-05	CcSEcCtD
Aripiprazole—Malaise—Methotrexate—breast cancer	1.38e-05	5.79e-05	CcSEcCtD
Aripiprazole—Muscle spasms—Epirubicin—breast cancer	1.38e-05	5.78e-05	CcSEcCtD
Aripiprazole—Immune system disorder—Doxorubicin—breast cancer	1.38e-05	5.77e-05	CcSEcCtD
Aripiprazole—Vertigo—Methotrexate—breast cancer	1.38e-05	5.77e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Capecitabine—breast cancer	1.38e-05	5.76e-05	CcSEcCtD
Aripiprazole—Mediastinal disorder—Doxorubicin—breast cancer	1.38e-05	5.76e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Docetaxel—breast cancer	1.37e-05	5.75e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Docetaxel—breast cancer	1.37e-05	5.75e-05	CcSEcCtD
Aripiprazole—Leukopenia—Methotrexate—breast cancer	1.37e-05	5.75e-05	CcSEcCtD
Aripiprazole—Chills—Doxorubicin—breast cancer	1.37e-05	5.73e-05	CcSEcCtD
Aripiprazole—Dizziness—Paclitaxel—breast cancer	1.36e-05	5.67e-05	CcSEcCtD
Aripiprazole—Vision blurred—Epirubicin—breast cancer	1.35e-05	5.66e-05	CcSEcCtD
Aripiprazole—Alopecia—Doxorubicin—breast cancer	1.35e-05	5.64e-05	CcSEcCtD
Aripiprazole—Cough—Methotrexate—breast cancer	1.34e-05	5.6e-05	CcSEcCtD
Aripiprazole—Mental disorder—Doxorubicin—breast cancer	1.34e-05	5.6e-05	CcSEcCtD
Aripiprazole—Urticaria—Capecitabine—breast cancer	1.34e-05	5.59e-05	CcSEcCtD
Aripiprazole—Ill-defined disorder—Epirubicin—breast cancer	1.33e-05	5.58e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Capecitabine—breast cancer	1.33e-05	5.56e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Capecitabine—breast cancer	1.33e-05	5.56e-05	CcSEcCtD
Aripiprazole—Convulsion—Methotrexate—breast cancer	1.33e-05	5.56e-05	CcSEcCtD
Aripiprazole—Erythema—Doxorubicin—breast cancer	1.33e-05	5.56e-05	CcSEcCtD
Aripiprazole—Malnutrition—Doxorubicin—breast cancer	1.33e-05	5.56e-05	CcSEcCtD
Aripiprazole—Anaemia—Epirubicin—breast cancer	1.33e-05	5.55e-05	CcSEcCtD
Aripiprazole—Agitation—Epirubicin—breast cancer	1.32e-05	5.52e-05	CcSEcCtD
Aripiprazole—Flatulence—Doxorubicin—breast cancer	1.31e-05	5.48e-05	CcSEcCtD
Aripiprazole—Arthralgia—Methotrexate—breast cancer	1.31e-05	5.47e-05	CcSEcCtD
Aripiprazole—Myalgia—Methotrexate—breast cancer	1.31e-05	5.47e-05	CcSEcCtD
Aripiprazole—Chest pain—Methotrexate—breast cancer	1.31e-05	5.47e-05	CcSEcCtD
Aripiprazole—Tension—Doxorubicin—breast cancer	1.3e-05	5.46e-05	CcSEcCtD
Aripiprazole—Vomiting—Paclitaxel—breast cancer	1.3e-05	5.45e-05	CcSEcCtD
Aripiprazole—Dysgeusia—Doxorubicin—breast cancer	1.3e-05	5.44e-05	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.3e-05	5.43e-05	CcSEcCtD
Aripiprazole—Malaise—Epirubicin—breast cancer	1.3e-05	5.42e-05	CcSEcCtD
Aripiprazole—Rash—Paclitaxel—breast cancer	1.29e-05	5.41e-05	CcSEcCtD
Aripiprazole—Dermatitis—Paclitaxel—breast cancer	1.29e-05	5.4e-05	CcSEcCtD
Aripiprazole—Discomfort—Methotrexate—breast cancer	1.29e-05	5.4e-05	CcSEcCtD
Aripiprazole—Nervousness—Doxorubicin—breast cancer	1.29e-05	5.4e-05	CcSEcCtD
Aripiprazole—Vertigo—Epirubicin—breast cancer	1.29e-05	5.4e-05	CcSEcCtD
Aripiprazole—Syncope—Epirubicin—breast cancer	1.29e-05	5.39e-05	CcSEcCtD
Aripiprazole—Leukopenia—Epirubicin—breast cancer	1.29e-05	5.38e-05	CcSEcCtD
Aripiprazole—Back pain—Doxorubicin—breast cancer	1.29e-05	5.38e-05	CcSEcCtD
Aripiprazole—Headache—Paclitaxel—breast cancer	1.28e-05	5.37e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Docetaxel—breast cancer	1.28e-05	5.36e-05	CcSEcCtD
Aripiprazole—Muscle spasms—Doxorubicin—breast cancer	1.28e-05	5.35e-05	CcSEcCtD
Aripiprazole—Palpitations—Epirubicin—breast cancer	1.27e-05	5.31e-05	CcSEcCtD
Aripiprazole—Confusional state—Methotrexate—breast cancer	1.26e-05	5.28e-05	CcSEcCtD
Aripiprazole—Loss of consciousness—Epirubicin—breast cancer	1.26e-05	5.28e-05	CcSEcCtD
Aripiprazole—Cough—Epirubicin—breast cancer	1.25e-05	5.24e-05	CcSEcCtD
Aripiprazole—Anaphylactic shock—Methotrexate—breast cancer	1.25e-05	5.24e-05	CcSEcCtD
Aripiprazole—Vision blurred—Doxorubicin—breast cancer	1.25e-05	5.24e-05	CcSEcCtD
Aripiprazole—Asthenia—Docetaxel—breast cancer	1.25e-05	5.22e-05	CcSEcCtD
Aripiprazole—Convulsion—Epirubicin—breast cancer	1.24e-05	5.21e-05	CcSEcCtD
Aripiprazole—Infection—Methotrexate—breast cancer	1.24e-05	5.21e-05	CcSEcCtD
Aripiprazole—Hypertension—Epirubicin—breast cancer	1.24e-05	5.19e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Capecitabine—breast cancer	1.24e-05	5.19e-05	CcSEcCtD
Aripiprazole—Ill-defined disorder—Doxorubicin—breast cancer	1.23e-05	5.16e-05	CcSEcCtD
Aripiprazole—Pruritus—Docetaxel—breast cancer	1.23e-05	5.14e-05	CcSEcCtD
Aripiprazole—Nervous system disorder—Methotrexate—breast cancer	1.23e-05	5.14e-05	CcSEcCtD
Aripiprazole—Anaemia—Doxorubicin—breast cancer	1.23e-05	5.14e-05	CcSEcCtD
Aripiprazole—Thrombocytopenia—Methotrexate—breast cancer	1.23e-05	5.13e-05	CcSEcCtD
Aripiprazole—Myalgia—Epirubicin—breast cancer	1.22e-05	5.12e-05	CcSEcCtD
Aripiprazole—Chest pain—Epirubicin—breast cancer	1.22e-05	5.12e-05	CcSEcCtD
Aripiprazole—Arthralgia—Epirubicin—breast cancer	1.22e-05	5.12e-05	CcSEcCtD
Aripiprazole—Agitation—Doxorubicin—breast cancer	1.22e-05	5.11e-05	CcSEcCtD
Aripiprazole—Anxiety—Epirubicin—breast cancer	1.22e-05	5.1e-05	CcSEcCtD
Aripiprazole—Nausea—Paclitaxel—breast cancer	1.22e-05	5.1e-05	CcSEcCtD
Aripiprazole—Skin disorder—Methotrexate—breast cancer	1.22e-05	5.09e-05	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.21e-05	5.08e-05	CcSEcCtD
Aripiprazole—Hyperhidrosis—Methotrexate—breast cancer	1.21e-05	5.07e-05	CcSEcCtD
Aripiprazole—Discomfort—Epirubicin—breast cancer	1.21e-05	5.05e-05	CcSEcCtD
Aripiprazole—Asthenia—Capecitabine—breast cancer	1.21e-05	5.05e-05	CcSEcCtD
Aripiprazole—Malaise—Doxorubicin—breast cancer	1.2e-05	5.01e-05	CcSEcCtD
Aripiprazole—Dry mouth—Epirubicin—breast cancer	1.2e-05	5e-05	CcSEcCtD
Aripiprazole—Vertigo—Doxorubicin—breast cancer	1.19e-05	5e-05	CcSEcCtD
Aripiprazole—Anorexia—Methotrexate—breast cancer	1.19e-05	5e-05	CcSEcCtD
Aripiprazole—Syncope—Doxorubicin—breast cancer	1.19e-05	4.99e-05	CcSEcCtD
Aripiprazole—Pruritus—Capecitabine—breast cancer	1.19e-05	4.98e-05	CcSEcCtD
Aripiprazole—Leukopenia—Doxorubicin—breast cancer	1.19e-05	4.98e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Docetaxel—breast cancer	1.19e-05	4.97e-05	CcSEcCtD
Aripiprazole—Confusional state—Epirubicin—breast cancer	1.18e-05	4.94e-05	CcSEcCtD
Aripiprazole—Palpitations—Doxorubicin—breast cancer	1.17e-05	4.91e-05	CcSEcCtD
Aripiprazole—Oedema—Epirubicin—breast cancer	1.17e-05	4.9e-05	CcSEcCtD
Aripiprazole—Anaphylactic shock—Epirubicin—breast cancer	1.17e-05	4.9e-05	CcSEcCtD
Aripiprazole—Hypotension—Methotrexate—breast cancer	1.17e-05	4.9e-05	CcSEcCtD
Aripiprazole—Loss of consciousness—Doxorubicin—breast cancer	1.17e-05	4.89e-05	CcSEcCtD
Aripiprazole—Infection—Epirubicin—breast cancer	1.16e-05	4.87e-05	CcSEcCtD
Aripiprazole—Cough—Doxorubicin—breast cancer	1.16e-05	4.85e-05	CcSEcCtD
Aripiprazole—Shock—Epirubicin—breast cancer	1.15e-05	4.82e-05	CcSEcCtD
Aripiprazole—Convulsion—Doxorubicin—breast cancer	1.15e-05	4.82e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Capecitabine—breast cancer	1.15e-05	4.82e-05	CcSEcCtD
Aripiprazole—Nervous system disorder—Epirubicin—breast cancer	1.15e-05	4.81e-05	CcSEcCtD
Aripiprazole—Dizziness—Docetaxel—breast cancer	1.15e-05	4.81e-05	CcSEcCtD
Aripiprazole—Thrombocytopenia—Epirubicin—breast cancer	1.15e-05	4.8e-05	CcSEcCtD
Aripiprazole—Hypertension—Doxorubicin—breast cancer	1.15e-05	4.8e-05	CcSEcCtD
Aripiprazole—Tachycardia—Epirubicin—breast cancer	1.14e-05	4.79e-05	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Methotrexate—breast cancer	1.14e-05	4.77e-05	CcSEcCtD
Aripiprazole—Skin disorder—Epirubicin—breast cancer	1.14e-05	4.76e-05	CcSEcCtD
Aripiprazole—Hyperhidrosis—Epirubicin—breast cancer	1.13e-05	4.74e-05	CcSEcCtD
Aripiprazole—Insomnia—Methotrexate—breast cancer	1.13e-05	4.74e-05	CcSEcCtD
Aripiprazole—Arthralgia—Doxorubicin—breast cancer	1.13e-05	4.73e-05	CcSEcCtD
Aripiprazole—Myalgia—Doxorubicin—breast cancer	1.13e-05	4.73e-05	CcSEcCtD
Aripiprazole—Chest pain—Doxorubicin—breast cancer	1.13e-05	4.73e-05	CcSEcCtD
Aripiprazole—Anxiety—Doxorubicin—breast cancer	1.13e-05	4.72e-05	CcSEcCtD
Aripiprazole—Paraesthesia—Methotrexate—breast cancer	1.12e-05	4.71e-05	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.12e-05	4.7e-05	CcSEcCtD
Aripiprazole—Discomfort—Doxorubicin—breast cancer	1.12e-05	4.68e-05	CcSEcCtD
Aripiprazole—Anorexia—Epirubicin—breast cancer	1.12e-05	4.67e-05	CcSEcCtD
Aripiprazole—Dyspnoea—Methotrexate—breast cancer	1.12e-05	4.67e-05	CcSEcCtD
Aripiprazole—Somnolence—Methotrexate—breast cancer	1.11e-05	4.66e-05	CcSEcCtD
Aripiprazole—Dizziness—Capecitabine—breast cancer	1.11e-05	4.66e-05	CcSEcCtD
Aripiprazole—Dry mouth—Doxorubicin—breast cancer	1.11e-05	4.63e-05	CcSEcCtD
Aripiprazole—Vomiting—Docetaxel—breast cancer	1.11e-05	4.62e-05	CcSEcCtD
Aripiprazole—Dyspepsia—Methotrexate—breast cancer	1.1e-05	4.61e-05	CcSEcCtD
Aripiprazole—Rash—Docetaxel—breast cancer	1.1e-05	4.58e-05	CcSEcCtD
Aripiprazole—Hypotension—Epirubicin—breast cancer	1.1e-05	4.58e-05	CcSEcCtD
Aripiprazole—Dermatitis—Docetaxel—breast cancer	1.09e-05	4.58e-05	CcSEcCtD
Aripiprazole—Confusional state—Doxorubicin—breast cancer	1.09e-05	4.58e-05	CcSEcCtD
Aripiprazole—Decreased appetite—Methotrexate—breast cancer	1.09e-05	4.56e-05	CcSEcCtD
Aripiprazole—Headache—Docetaxel—breast cancer	1.09e-05	4.55e-05	CcSEcCtD
Aripiprazole—Oedema—Doxorubicin—breast cancer	1.08e-05	4.54e-05	CcSEcCtD
Aripiprazole—Anaphylactic shock—Doxorubicin—breast cancer	1.08e-05	4.54e-05	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Methotrexate—breast cancer	1.08e-05	4.52e-05	CcSEcCtD
Aripiprazole—Fatigue—Methotrexate—breast cancer	1.08e-05	4.52e-05	CcSEcCtD
Aripiprazole—Infection—Doxorubicin—breast cancer	1.08e-05	4.51e-05	CcSEcCtD
Aripiprazole—Pain—Methotrexate—breast cancer	1.07e-05	4.48e-05	CcSEcCtD
Aripiprazole—Vomiting—Capecitabine—breast cancer	1.07e-05	4.48e-05	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Epirubicin—breast cancer	1.07e-05	4.47e-05	CcSEcCtD
Aripiprazole—Shock—Doxorubicin—breast cancer	1.07e-05	4.46e-05	CcSEcCtD
Aripiprazole—Nervous system disorder—Doxorubicin—breast cancer	1.06e-05	4.45e-05	CcSEcCtD
Aripiprazole—Thrombocytopenia—Doxorubicin—breast cancer	1.06e-05	4.44e-05	CcSEcCtD
Aripiprazole—Rash—Capecitabine—breast cancer	1.06e-05	4.44e-05	CcSEcCtD
Aripiprazole—Insomnia—Epirubicin—breast cancer	1.06e-05	4.44e-05	CcSEcCtD
Aripiprazole—Dermatitis—Capecitabine—breast cancer	1.06e-05	4.43e-05	CcSEcCtD
Aripiprazole—Tachycardia—Doxorubicin—breast cancer	1.06e-05	4.43e-05	CcSEcCtD
Aripiprazole—Headache—Capecitabine—breast cancer	1.05e-05	4.41e-05	CcSEcCtD
Aripiprazole—Skin disorder—Doxorubicin—breast cancer	1.05e-05	4.41e-05	CcSEcCtD
Aripiprazole—Paraesthesia—Epirubicin—breast cancer	1.05e-05	4.4e-05	CcSEcCtD
Aripiprazole—Hyperhidrosis—Doxorubicin—breast cancer	1.05e-05	4.39e-05	CcSEcCtD
Aripiprazole—Dyspnoea—Epirubicin—breast cancer	1.05e-05	4.37e-05	CcSEcCtD
Aripiprazole—Somnolence—Epirubicin—breast cancer	1.04e-05	4.36e-05	CcSEcCtD
Aripiprazole—Anorexia—Doxorubicin—breast cancer	1.03e-05	4.33e-05	CcSEcCtD
Aripiprazole—Nausea—Docetaxel—breast cancer	1.03e-05	4.32e-05	CcSEcCtD
Aripiprazole—Feeling abnormal—Methotrexate—breast cancer	1.03e-05	4.32e-05	CcSEcCtD
Aripiprazole—Dyspepsia—Epirubicin—breast cancer	1.03e-05	4.32e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Methotrexate—breast cancer	1.02e-05	4.29e-05	CcSEcCtD
Aripiprazole—Decreased appetite—Epirubicin—breast cancer	1.02e-05	4.26e-05	CcSEcCtD
Aripiprazole—Hypotension—Doxorubicin—breast cancer	1.01e-05	4.24e-05	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Epirubicin—breast cancer	1.01e-05	4.23e-05	CcSEcCtD
Aripiprazole—Fatigue—Epirubicin—breast cancer	1.01e-05	4.23e-05	CcSEcCtD
Aripiprazole—Constipation—Epirubicin—breast cancer	1e-05	4.19e-05	CcSEcCtD
Aripiprazole—Pain—Epirubicin—breast cancer	1e-05	4.19e-05	CcSEcCtD
Aripiprazole—Nausea—Capecitabine—breast cancer	9.99e-06	4.18e-05	CcSEcCtD
Aripiprazole—Urticaria—Methotrexate—breast cancer	9.95e-06	4.16e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Methotrexate—breast cancer	9.9e-06	4.14e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Methotrexate—breast cancer	9.9e-06	4.14e-05	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Doxorubicin—breast cancer	9.88e-06	4.13e-05	CcSEcCtD
Aripiprazole—Insomnia—Doxorubicin—breast cancer	9.81e-06	4.1e-05	CcSEcCtD
Aripiprazole—Paraesthesia—Doxorubicin—breast cancer	9.74e-06	4.07e-05	CcSEcCtD
Aripiprazole—Dyspnoea—Doxorubicin—breast cancer	9.67e-06	4.05e-05	CcSEcCtD
Aripiprazole—Feeling abnormal—Epirubicin—breast cancer	9.66e-06	4.04e-05	CcSEcCtD
Aripiprazole—Somnolence—Doxorubicin—breast cancer	9.64e-06	4.03e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Epirubicin—breast cancer	9.59e-06	4.01e-05	CcSEcCtD
Aripiprazole—Dyspepsia—Doxorubicin—breast cancer	9.55e-06	3.99e-05	CcSEcCtD
Aripiprazole—Decreased appetite—Doxorubicin—breast cancer	9.43e-06	3.94e-05	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Doxorubicin—breast cancer	9.36e-06	3.92e-05	CcSEcCtD
Aripiprazole—Fatigue—Doxorubicin—breast cancer	9.35e-06	3.91e-05	CcSEcCtD
Aripiprazole—Urticaria—Epirubicin—breast cancer	9.31e-06	3.9e-05	CcSEcCtD
Aripiprazole—Constipation—Doxorubicin—breast cancer	9.28e-06	3.88e-05	CcSEcCtD
Aripiprazole—Pain—Doxorubicin—breast cancer	9.28e-06	3.88e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Epirubicin—breast cancer	9.27e-06	3.88e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Epirubicin—breast cancer	9.27e-06	3.88e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Methotrexate—breast cancer	9.23e-06	3.86e-05	CcSEcCtD
Aripiprazole—Asthenia—Methotrexate—breast cancer	8.99e-06	3.76e-05	CcSEcCtD
Aripiprazole—Feeling abnormal—Doxorubicin—breast cancer	8.94e-06	3.74e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Doxorubicin—breast cancer	8.87e-06	3.71e-05	CcSEcCtD
Aripiprazole—Pruritus—Methotrexate—breast cancer	8.86e-06	3.71e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Epirubicin—breast cancer	8.64e-06	3.61e-05	CcSEcCtD
Aripiprazole—Urticaria—Doxorubicin—breast cancer	8.62e-06	3.6e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Doxorubicin—breast cancer	8.57e-06	3.59e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Doxorubicin—breast cancer	8.57e-06	3.59e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Methotrexate—breast cancer	8.57e-06	3.59e-05	CcSEcCtD
Aripiprazole—Asthenia—Epirubicin—breast cancer	8.41e-06	3.52e-05	CcSEcCtD
Aripiprazole—Pruritus—Epirubicin—breast cancer	8.29e-06	3.47e-05	CcSEcCtD
Aripiprazole—Dizziness—Methotrexate—breast cancer	8.28e-06	3.47e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Epirubicin—breast cancer	8.02e-06	3.36e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Doxorubicin—breast cancer	7.99e-06	3.34e-05	CcSEcCtD
Aripiprazole—Vomiting—Methotrexate—breast cancer	7.96e-06	3.33e-05	CcSEcCtD
Aripiprazole—Rash—Methotrexate—breast cancer	7.9e-06	3.3e-05	CcSEcCtD
Aripiprazole—Dermatitis—Methotrexate—breast cancer	7.89e-06	3.3e-05	CcSEcCtD
Aripiprazole—Headache—Methotrexate—breast cancer	7.85e-06	3.28e-05	CcSEcCtD
Aripiprazole—Asthenia—Doxorubicin—breast cancer	7.78e-06	3.26e-05	CcSEcCtD
Aripiprazole—Dizziness—Epirubicin—breast cancer	7.75e-06	3.24e-05	CcSEcCtD
Aripiprazole—Pruritus—Doxorubicin—breast cancer	7.67e-06	3.21e-05	CcSEcCtD
Aripiprazole—Vomiting—Epirubicin—breast cancer	7.45e-06	3.12e-05	CcSEcCtD
Aripiprazole—Nausea—Methotrexate—breast cancer	7.44e-06	3.11e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Doxorubicin—breast cancer	7.42e-06	3.1e-05	CcSEcCtD
Aripiprazole—Rash—Epirubicin—breast cancer	7.39e-06	3.09e-05	CcSEcCtD
Aripiprazole—Dermatitis—Epirubicin—breast cancer	7.38e-06	3.09e-05	CcSEcCtD
Aripiprazole—Headache—Epirubicin—breast cancer	7.34e-06	3.07e-05	CcSEcCtD
Aripiprazole—Dizziness—Doxorubicin—breast cancer	7.17e-06	3e-05	CcSEcCtD
Aripiprazole—Nausea—Epirubicin—breast cancer	6.96e-06	2.91e-05	CcSEcCtD
Aripiprazole—Vomiting—Doxorubicin—breast cancer	6.9e-06	2.89e-05	CcSEcCtD
Aripiprazole—Rash—Doxorubicin—breast cancer	6.84e-06	2.86e-05	CcSEcCtD
Aripiprazole—Dermatitis—Doxorubicin—breast cancer	6.83e-06	2.86e-05	CcSEcCtD
Aripiprazole—Headache—Doxorubicin—breast cancer	6.8e-06	2.84e-05	CcSEcCtD
Aripiprazole—Nausea—Doxorubicin—breast cancer	6.44e-06	2.7e-05	CcSEcCtD
Aripiprazole—DRD4—Signaling Pathways—HRAS—breast cancer	1.03e-06	8.62e-06	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—IL6—breast cancer	1.03e-06	8.62e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—AKT1—breast cancer	1.03e-06	8.62e-06	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—EGFR—breast cancer	1.03e-06	8.61e-06	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—TP53—breast cancer	1.03e-06	8.61e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—AKT1—breast cancer	1.03e-06	8.6e-06	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—PIK3CA—breast cancer	1.03e-06	8.6e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—MAPK8—breast cancer	1.02e-06	8.6e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—ABCB1—breast cancer	1.02e-06	8.58e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—AKT1—breast cancer	1.02e-06	8.57e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MAPK8—breast cancer	1.02e-06	8.57e-06	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—IL6—breast cancer	1.02e-06	8.56e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CASP3—breast cancer	1.02e-06	8.55e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—AKT1—breast cancer	1.02e-06	8.54e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—IL2—breast cancer	1.02e-06	8.54e-06	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—TP53—breast cancer	1.02e-06	8.52e-06	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—HRAS—breast cancer	1.01e-06	8.5e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—IL6—breast cancer	1.01e-06	8.5e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—MYC—breast cancer	1.01e-06	8.5e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MAPK8—breast cancer	1.01e-06	8.48e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—TGFB1—breast cancer	1.01e-06	8.48e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—AKT1—breast cancer	1.01e-06	8.46e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MAPK8—breast cancer	1.01e-06	8.46e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—MAPK3—breast cancer	1.01e-06	8.45e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—MYC—breast cancer	1.01e-06	8.45e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—AKT1—breast cancer	1.01e-06	8.44e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—TGFB1—breast cancer	1.01e-06	8.43e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—TYMS—breast cancer	1e-06	8.43e-06	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—PIK3CA—breast cancer	1e-06	8.39e-06	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—IL6—breast cancer	1e-06	8.39e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—PIK3CA—breast cancer	9.95e-07	8.35e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—NOS3—breast cancer	9.94e-07	8.33e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PLA2G4A—breast cancer	9.93e-07	8.33e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—NCOR1—breast cancer	9.93e-07	8.33e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—GSTM1—breast cancer	9.93e-07	8.33e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CCND1—breast cancer	9.93e-07	8.33e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—SRC—breast cancer	9.93e-07	8.33e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—MAPK3—breast cancer	9.92e-07	8.32e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PIK3CD—breast cancer	9.92e-07	8.32e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—EGFR—breast cancer	9.91e-07	8.31e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—JUN—breast cancer	9.91e-07	8.31e-06	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—PIK3CA—breast cancer	9.87e-07	8.28e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—EGFR—breast cancer	9.86e-07	8.27e-06	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—IL6—breast cancer	9.84e-07	8.25e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	9.83e-07	8.25e-06	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—HRAS—breast cancer	9.81e-07	8.23e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—MYC—breast cancer	9.81e-07	8.22e-06	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—KRAS—breast cancer	9.79e-07	8.21e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—ALB—breast cancer	9.79e-07	8.21e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—TGFB1—breast cancer	9.78e-07	8.2e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—SRC—breast cancer	9.77e-07	8.19e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—SRC—breast cancer	9.75e-07	8.17e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—SRC—breast cancer	9.72e-07	8.15e-06	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—HRAS—breast cancer	9.71e-07	8.14e-06	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—IL6—breast cancer	9.71e-07	8.14e-06	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—KRAS—breast cancer	9.7e-07	8.13e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—SRC—breast cancer	9.69e-07	8.12e-06	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—TP53—breast cancer	9.68e-07	8.12e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—VEGFA—breast cancer	9.67e-07	8.11e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—MYC—breast cancer	9.65e-07	8.09e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MMP9—breast cancer	9.64e-07	8.08e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—TGFB1—breast cancer	9.63e-07	8.07e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	9.61e-07	8.05e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—SRC—breast cancer	9.59e-07	8.04e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—EGFR—breast cancer	9.59e-07	8.04e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—PTEN—breast cancer	9.58e-07	8.04e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—STAT3—breast cancer	9.57e-07	8.03e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—SRC—breast cancer	9.57e-07	8.02e-06	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—TP53—breast cancer	9.55e-07	8.01e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—VEGFA—breast cancer	9.51e-07	7.98e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—GPX1—breast cancer	9.51e-07	7.98e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—VEGFA—breast cancer	9.49e-07	7.96e-06	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—AKT1—breast cancer	9.49e-07	7.96e-06	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—AKT1—breast cancer	9.48e-07	7.95e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—VEGFA—breast cancer	9.46e-07	7.94e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—EGFR—breast cancer	9.44e-07	7.92e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—VEGFA—breast cancer	9.43e-07	7.91e-06	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—AKT1—breast cancer	9.42e-07	7.9e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—STAT3—breast cancer	9.42e-07	7.9e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—CYP1A1—breast cancer	9.41e-07	7.9e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—STAT3—breast cancer	9.4e-07	7.88e-06	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—IL6—breast cancer	9.39e-07	7.88e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MAPK8—breast cancer	9.38e-07	7.86e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—STAT3—breast cancer	9.37e-07	7.86e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—NOS3—breast cancer	9.36e-07	7.85e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—KRAS—breast cancer	9.36e-07	7.85e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—AKT1—breast cancer	9.35e-07	7.84e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—VEGFA—breast cancer	9.34e-07	7.83e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—STAT3—breast cancer	9.34e-07	7.83e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—ERCC2—breast cancer	9.34e-07	7.83e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—VEGFA—breast cancer	9.32e-07	7.81e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—KRAS—breast cancer	9.31e-07	7.81e-06	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—IL6—breast cancer	9.3e-07	7.8e-06	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—HRAS—breast cancer	9.25e-07	7.76e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—STAT3—breast cancer	9.25e-07	7.76e-06	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—AKT1—breast cancer	9.22e-07	7.74e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—STAT3—breast cancer	9.22e-07	7.74e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PIK3CB—breast cancer	9.17e-07	7.69e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—MAPK3—breast cancer	9.15e-07	7.67e-06	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—HRAS—breast cancer	9.13e-07	7.66e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PTGS2—breast cancer	9.09e-07	7.62e-06	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—AKT1—breast cancer	9.08e-07	7.61e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—KRAS—breast cancer	9.06e-07	7.6e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—MAPK3—breast cancer	9e-07	7.55e-06	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—PIK3CA—breast cancer	8.99e-07	7.54e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—MAPK3—breast cancer	8.98e-07	7.53e-06	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—AKT1—breast cancer	8.96e-07	7.51e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—MAPK3—breast cancer	8.95e-07	7.51e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MAPK3—breast cancer	8.92e-07	7.48e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—KRAS—breast cancer	8.92e-07	7.48e-06	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—PIK3CA—breast cancer	8.91e-07	7.47e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—MYC—breast cancer	8.9e-07	7.46e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—SRC—breast cancer	8.89e-07	7.45e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—TGFB1—breast cancer	8.88e-07	7.44e-06	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—IL6—breast cancer	8.86e-07	7.43e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MAPK3—breast cancer	8.84e-07	7.41e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MAPK3—breast cancer	8.81e-07	7.39e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—PIK3CA—breast cancer	8.81e-07	7.39e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—MTHFR—breast cancer	8.78e-07	7.36e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—MYC—breast cancer	8.75e-07	7.34e-06	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—IL6—breast cancer	8.74e-07	7.33e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—MYC—breast cancer	8.74e-07	7.33e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—TGFB1—breast cancer	8.73e-07	7.32e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—TGFB1—breast cancer	8.71e-07	7.31e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—MYC—breast cancer	8.71e-07	7.3e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—EGFR—breast cancer	8.7e-07	7.3e-06	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—TP53—breast cancer	8.7e-07	7.3e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—TGFB1—breast cancer	8.69e-07	7.28e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MYC—breast cancer	8.68e-07	7.28e-06	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—AKT1—breast cancer	8.67e-07	7.27e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—TGFB1—breast cancer	8.66e-07	7.26e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—VEGFA—breast cancer	8.66e-07	7.26e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PIK3CB—breast cancer	8.64e-07	7.25e-06	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—TP53—breast cancer	8.62e-07	7.23e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—PIK3CA—breast cancer	8.6e-07	7.21e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MYC—breast cancer	8.6e-07	7.21e-06	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—AKT1—breast cancer	8.58e-07	7.19e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—TGFB1—breast cancer	8.57e-07	7.19e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MYC—breast cancer	8.57e-07	7.19e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—STAT3—breast cancer	8.57e-07	7.19e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PTGS2—breast cancer	8.56e-07	7.18e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—EGFR—breast cancer	8.56e-07	7.18e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—PIK3CA—breast cancer	8.56e-07	7.18e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—TGFB1—breast cancer	8.55e-07	7.17e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—EGFR—breast cancer	8.54e-07	7.16e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—EGFR—breast cancer	8.52e-07	7.14e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—EGFR—breast cancer	8.49e-07	7.12e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—EGFR—breast cancer	8.41e-07	7.05e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—EGFR—breast cancer	8.38e-07	7.03e-06	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—AKT1—breast cancer	8.37e-07	7.02e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—PIK3CA—breast cancer	8.32e-07	6.98e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—TP53—breast cancer	8.32e-07	6.98e-06	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—HRAS—breast cancer	8.32e-07	6.98e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—TP53—breast cancer	8.28e-07	6.94e-06	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—HRAS—breast cancer	8.24e-07	6.91e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—KRAS—breast cancer	8.22e-07	6.89e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—PIK3CA—breast cancer	8.19e-07	6.87e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MAPK3—breast cancer	8.19e-07	6.87e-06	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—AKT1—breast cancer	8.17e-07	6.85e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—AKT1—breast cancer	8.13e-07	6.82e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—CAV1—breast cancer	8.1e-07	6.79e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—KRAS—breast cancer	8.09e-07	6.78e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—PIK3CA—breast cancer	8.09e-07	6.78e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—KRAS—breast cancer	8.07e-07	6.77e-06	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—AKT1—breast cancer	8.06e-07	6.76e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—TP53—breast cancer	8.05e-07	6.75e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—KRAS—breast cancer	8.05e-07	6.75e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—KRAS—breast cancer	8.02e-07	6.73e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MYC—breast cancer	7.96e-07	6.68e-06	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—IL6—breast cancer	7.96e-07	6.68e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—HRAS—breast cancer	7.96e-07	6.67e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—TGFB1—breast cancer	7.94e-07	6.66e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—KRAS—breast cancer	7.94e-07	6.66e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PTEN—breast cancer	7.93e-07	6.65e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—TP53—breast cancer	7.92e-07	6.65e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—KRAS—breast cancer	7.92e-07	6.64e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—HRAS—breast cancer	7.92e-07	6.64e-06	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—IL6—breast cancer	7.89e-07	6.62e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—EGFR—breast cancer	7.79e-07	6.53e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—HRAS—breast cancer	7.7e-07	6.46e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—IL6—breast cancer	7.62e-07	6.39e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—HRAS—breast cancer	7.58e-07	6.36e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—IL6—breast cancer	7.58e-07	6.35e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—PIK3CA—breast cancer	7.55e-07	6.33e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PTEN—breast cancer	7.47e-07	6.26e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—PIK3CA—breast cancer	7.43e-07	6.23e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—PIK3CA—breast cancer	7.42e-07	6.22e-06	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—PIK3CA—breast cancer	7.41e-07	6.21e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—PIK3CA—breast cancer	7.39e-07	6.2e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CG—breast cancer	7.37e-07	6.18e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—IL6—breast cancer	7.37e-07	6.18e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—PIK3CA—breast cancer	7.37e-07	6.18e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—KRAS—breast cancer	7.36e-07	6.17e-06	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—AKT1—breast cancer	7.35e-07	6.16e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—TP53—breast cancer	7.31e-07	6.13e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—PIK3CA—breast cancer	7.3e-07	6.12e-06	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—AKT1—breast cancer	7.28e-07	6.1e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—PIK3CA—breast cancer	7.28e-07	6.1e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—IL6—breast cancer	7.25e-07	6.08e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—AKT1—breast cancer	7.2e-07	6.04e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—TP53—breast cancer	7.19e-07	6.03e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—TP53—breast cancer	7.17e-07	6.02e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—TP53—breast cancer	7.15e-07	6e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—TP53—breast cancer	7.13e-07	5.98e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—TP53—breast cancer	7.06e-07	5.92e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—TP53—breast cancer	7.04e-07	5.9e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—AKT1—breast cancer	7.03e-07	5.89e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—AKT1—breast cancer	6.99e-07	5.86e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—HRAS—breast cancer	6.99e-07	5.86e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—HRAS—breast cancer	6.88e-07	5.77e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—HRAS—breast cancer	6.86e-07	5.75e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—HRAS—breast cancer	6.84e-07	5.73e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—HRAS—breast cancer	6.82e-07	5.72e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—AKT1—breast cancer	6.8e-07	5.7e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	6.76e-07	5.67e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—HRAS—breast cancer	6.75e-07	5.66e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—HRAS—breast cancer	6.73e-07	5.65e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—AKT1—breast cancer	6.69e-07	5.61e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—IL6—breast cancer	6.69e-07	5.61e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—AKT1—breast cancer	6.61e-07	5.54e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—IL6—breast cancer	6.58e-07	5.52e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—IL6—breast cancer	6.57e-07	5.51e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—IL6—breast cancer	6.55e-07	5.49e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—TP53—breast cancer	6.54e-07	5.48e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—IL6—breast cancer	6.52e-07	5.47e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CD—breast cancer	6.48e-07	5.44e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—IL6—breast cancer	6.46e-07	5.42e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—IL6—breast cancer	6.44e-07	5.4e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—ALB—breast cancer	6.4e-07	5.37e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—HRAS—breast cancer	6.26e-07	5.25e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—AKT1—breast cancer	6.17e-07	5.17e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—NOS3—breast cancer	6.12e-07	5.13e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—AKT1—breast cancer	6.07e-07	5.09e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—AKT1—breast cancer	6.06e-07	5.08e-06	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—AKT1—breast cancer	6.05e-07	5.08e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—AKT1—breast cancer	6.04e-07	5.06e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—AKT1—breast cancer	6.02e-07	5.05e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—IL6—breast cancer	5.99e-07	5.02e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—AKT1—breast cancer	5.96e-07	5e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—AKT1—breast cancer	5.94e-07	4.98e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CB—breast cancer	5.65e-07	4.74e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PTGS2—breast cancer	5.6e-07	4.7e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PIK3CA—breast cancer	5.59e-07	4.69e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—AKT1—breast cancer	5.52e-07	4.63e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PIK3CA—breast cancer	5.27e-07	4.42e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PTEN—breast cancer	4.88e-07	4.09e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—AKT1—breast cancer	4.57e-07	3.83e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—AKT1—breast cancer	4.3e-07	3.61e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CA—breast cancer	3.44e-07	2.89e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—AKT1—breast cancer	2.81e-07	2.36e-06	CbGpPWpGaD
